UK ‘underprepared’ to realise RegenMed benefits, say Lords Science Committee

1 Jul 2013

Regenerative medicine has the potential to make a real contribution to public health and the economy in the UK, according to the House of Lords Science and Technology Committee's report on regenerative medicine. UK ‘underprepared’ to realise RegenMed benefits, say Lords Science Committee

But, while the Committee point to the potential of regenmed to treat a range of chronic diseases, it also finds that the UK is underprepared to realise the potential health and economic benefits.

The report finds that a lack of co-ordinated leadership and complex regulatory arrangements, as well as inappropriate funding models, may be holding back the UK from taking a world-leading position in regenerative medicine.

It recommends:
• streamlining of the regulatory system for regenerative medicine;
• developing a strategy to ensure that the NHS is ready to provide regenerative medicine treatments;
• creating innovative funding models to support the sector’s development;
• increased support from the National Institute for Health Research (NIHR) for clinical trials; and
• greater investment in manufacturing facilities to support scale-up and clinical development.

Regener8 and its strategic partner, the Medical Technologies IKC, submitted written evidence to the enquiry. Dr Mike Raxworthy, Regener8 Operations Director commented:

“Regener8 endorses the recognition made by this report that the UK could benefit from the significant health and economic benefits that regenerative medicine can offer.

“The UK is in a strong position in many areas of regenerative medicine thanks to the world-class science base in our universities and the leading expertise among many UK companies and clinicians in relation to translation, commercialisation and application, and as a result, a number of regenerative therapies are now making their way to the clinic. We recognise, however, that there are still significant gaps and barriers in the process to commercialisation.

“We welcome the Committee’s call to streamline the regulatory system and explore new, innovative funding models in order to develop the UK’s regenerative medicine sector. In particular, we welcome the recommendation for the NIHR to establish a regenerative medicine clinical research programme and for a strategy to be developed to ensure more regenerative treatments are delivered through the NHS so that patients can benefit.

“We are grateful to have had the opportunity to submit evidence to the enquiry and pleased to see that much of our evidence has been considered by the Committee, and we look forward to the opportunity to help implement the report’s recommendations in whichever way we are invited to do so. Regener8 remains committed to raising the capability required in both the public and private sectors to ensure the UK is fully prepared to exploit the benefits of regenerative medicine.”

Read the full report here.

Read background on the House of Lords Science and Technology Committee enquiry into regenerative medicine here.


Back to main news